Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses value and patient co-payment assistance programs.
Transcript:
Are patient-assistance programs on the whole good or bad?
Well, we know that many of our community members rely on them to receive their therapy, so they’re very important. I think what is also important with patient-assistance programs is understanding that sometimes they can be abused. Our fear is that when they are abused, or when they’re used by individuals that may not actually need them, so to speak, it could compromise patient-assistance programs in general for the folks that are most vulnerable and need them.
I would point to a white paper that our organization did in collaboration with the University of Michigan [Center for Value-Based Insurance Design]. It looks at precision patient-assistance programs [and] how we can identify those vulnerable patients most at risk from a clinical standpoint and from a financial standpoint and making sure that co-pay assistance programs are available specifically to those individuals so that we can get people on the right treatment quickly.
I think it’s a balance. I think we need to be more responsible about applying co-pay assistance programs to individuals so that we can guarantee that they’ll be around for a longer period of time.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.